Results 131 to 140 of about 2,570,930 (351)
Producing MSCs on rigid culture substrates induces a scar‐making phenotype, jeapordizing therapeutic success. ‘Tissue‐soft’ surfaces prevent MSC fibrogenesis and preserve regenerative traits. An epigenetic network, driven by HOXA11 and SALL1, maintains ‘soft memory’ by keeping chromatin open in relaxed MSCs, promoting anti‐fibrotic programs.
Fereshteh Sadat Younesi +7 more
wiley +1 more source
Late follow-up after thoracic duct drainage in cadaveric renal transplantation [PDF]
Thoracic duct drainage was added to conventional immunosuppression with azathioprine, prednisone and, sometimes, antilymphocyte globulin in 83 patients given cadaveric kidneys, including 65 primary graft recipients.
Iwatsuki, S +4 more
core
The challenge of urinary tract infections in renal transplant recipients
Ian Hollyer, M. Ison
semanticscholar +1 more source
This study reports the development of a fully humanized bispecific T cell engager targeting IL13RA2, a tumor‐associated antigen enriched in glioblastoma. This off‐the‐shelf immunotherapy drives potent, antigen‐dependent T cell activation and tumor killing, and prolongs survival in experimental GBM and other solid tumors models without detectable off ...
Joseph T. Duffy +16 more
wiley +1 more source
In this study, a MXene‐based V4C3 nanoplatform, VARH, was constructed, which achieved a photothermal conversion efficiency of 44.21% in the NIR‐II window. This platform integrated photothermal therapy, chemodynamic therapy, and thermodynamic therapy with CRISPR/Cas9‐mediated heat shock protein 90 knock‐out technology.
Zi‐Jian Huang +8 more
wiley +1 more source
Mesenchymal stromal cells (MSCs) show promise for treating immune‐related disorders through immunomodulation and tissue regeneration. This review gives a brief overview of current clinical approval of MSC therapies. It also discussed how bioengineering, including genetic modification, biomaterial delivery, extracellular vesicles, and iPSC‐derived MSCs,
Sichen Yang +6 more
wiley +1 more source
A dual‐network bFGF@CB‐gel integrates: i) ChSMA scaffold (mechanical support/BMSCs delivery); ii) BC carrier (sustained bFGF release via EGFL/Itga2b and COMP/PI3K/AKT for adhesion/osteogenesis); iii) bFGF/PI3K/AKT/eNOS for angiogenesis. This rational, synergistic design addresses CSD bone regeneration challenges.
Yunze Feng +12 more
wiley +1 more source
Background A number of UK transplantation centres use isotope studies to estimate the relative contribution from each kidney in living kidney donor assessment.
Kirsty J. Crowe +6 more
doaj +1 more source
This review surveys nanoparticle‐based strategies to enhance adoptive cell therapy, particularly CAR‐T cell approaches, in solid tumor treatment. It describes how nanoparticles can improve tumor immunogenicity and T‐cell infiltration while reducing toxicity, and how they enable in vivo CAR‐T cell generation.
Erica Frostegård +19 more
wiley +1 more source

